Probiotics in inflammatory bowel disease: Is it all gut flora modulation?

Gut

Volumn 53, Issue 5, 2004, Pages 620-622

  Ghosh, S ^a   Van Heel, D ^a   Playford, R J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOCIN; PROBIOTIC AGENT;

BIFIDOBACTERIUM; CYTOKINE PRODUCTION; ENTERITIS; GENE MUTATION; GENOME; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INTESTINE FLORA; KNOCKOUT MOUSE; LACTOBACILLUS; NONHUMAN; NOTE; PRIORITY JOURNAL;

ANIMALS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MICE; PROBIOTICS;

EID: 2342423210     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.034249     Document Type: Note

References (28)

1. Ghosh S, Playford RJ. Bioactive natural compounds for the treatment of gastrointestinal disorders. Clin Sci (Lond) 2003;104:547-6.
2. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-9.
3. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14.
4. Venturi A, Gionchetti P, Rizzelo F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-8.
5. Prantera C, Scribano ML, Falasco G, et al. Lactobacillus GG did not prevent endoscopic recurrence at one year nor reduced the severity of recurrent lesions. Gut 2002;51:405-9.
6. Ahrne S, Nobaek S, Jeppsson B, et al. The normal lactobacillus flora of healthy human rectal and oral mucosa. J Appl Microbiol 1988;85:88.
7. Perdigon G, Galdeano CM, Valdez JC, et al. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr 2002;56(suppl 4):S21-6.
8. Mizoguchi A, Mizoguchi E, Bhan AK. Immune networks in animal models of inflammatory bowel disease. Inflamm Bowel Dis 2003;9:246-59.
9. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-14.
10. McCarthy J, O'Mahony L, O'Callaghan L, et al. Double blind placebo-controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975-980.
11. Dieleman LA, Goerres MS, Arendis A, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003;52:370-6.
12. Sheil R, McCarthy J, O'Mahony L, et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004;53:694-700.
13. Borruel N, Carol M, Casellas F, et al. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659-64.
14. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003;52:988-97.
15. Boudeau J, Glasser AL, Julien S, et al. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E.coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:45-56.
16. Rachmilewitz D, Karmeli F, Tokbayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterelogy 2002;122:1428-41.
17. Rachmilewitz D, Katokuro K, Karmeli F, et al. Toll-like receptor 9 signalling mediates the anti-inflammatory affects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-8.
18. Lammers KM, Brigidi P, Vitoli B, et al. Immunomodulatory effects of probiotic bacteria DNA: IL-10 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol 2003;38:165-72.
19. Kitazawa H, Watanabe H, Shimosato T, et al. Immunostimulatory oliganucleotide CpG-like motif exists in Lactobacillus delbrueckii ssp. bulgaricus NIAI B6. Int J Food Microbiol 2003;83:11-21.
20. Flynn S, van Sinderen O, Thornton GM, et al. Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. Salivarius UCC118 Microbiology 2002;148:973-984.
21. Gardiner GE, O'Sullivan E, Kelly J, et al. Comparative survival rates of human-derived probiotic Lactobacillus paracasei and L. salivarius strains during heat treatment and spray drying. Appl Environ Microbiol 2000;66:2605-12.
22. Christensen HR, Frokiaer H, Pestka JJ. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 2002;168:171-8.
23. 1 cell chemotaxis. J Leukoc Biol 2003;74:395-402.
24. Schultz M, Lindo HJ, Lehn N, et al. Immunostimulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res 2003;70:165-73.
25. Ogura Y, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
26. Hugot JP, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
27. Inohara N, et al. Host recognition of bacterial muromyl dipeptide mediated through NOD2: implications for Crohn's disease. J Biol Chem 2003;278:5509-12.
28. Girardin SE, Travassos LH, Herve M, et al. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 2003;278:41702-8.